Abstract
Neuroendocrine neoplasms arise in almost every organ of the body and are variably defined according to the site of origin. This Review focuses on neuroendocrine neoplasms of the digestive tract and pancreas. The 2010 WHO classification of tumors of the digestive system introduces grading and staging tools for neuroendocrine neoplasms. A carcinoid is now defined as a grade 1 or 2 neuroendocrine tumor and grade 3, small-cell or large-cell carcinomas are defined as neuroendocrine carcinoma. Epidemiological data show a worldwide increase in the prevalence and incidence of gastroentero-pancreatic neuroendocrine tumors in the past few decades, which is probably due to improved methods of detection of these tumors. The current diagnostic procedures and treatment options for neuroendocrine neoplasms are defined and summarized in the Review, although evidence-based data are lacking. Surgery remains the treatment mainstay and somatostatin analogues the basis for both diagnosis and therapy as the only 'theranostic' tool. Emerging compounds including chemotherapeutic agents, small molecules and biological therapies may provide new hope for patients.
Key Points
-
Two regulated pathways of secretion are found in neuroendocrine cells that share features of secretory pathways found in endocrine cells and nerve cells
-
The WHO 2010 neuroendocrine neoplasm classification has introduced grading and staging; low to intermediate grade tumors are defined as neuroendocrine tumors (previously carcinoids) whereas high-grade carcinomas are termed neuroendocrine carcinomas
-
Gut and pancreas stem cells are fairly well defined, but data are lacking to support the cancer stem cell theory in neuroendocrine neoplasms
-
Therapy mainstays for gut and pancreas neuroendocrine neoplasms include surgery and the use of somatostatin analogues
-
Questions remain concerning both diagnosis and treatment of these neoplasms in current clinical practice because of a lack of evidence-based studies
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
13 December 2011
In the version of this article initially published online, in Table 2, the value for the Ki-67 index (%) for NET Grade 1 should have read ≤2 instead of <2. The error has been corrected for the HTML and PDF versions of the article.
References
Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).
Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T. & Snyderwine, E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J. Natl Cancer Inst. 100, 1282–1289 (2008).
Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. (Eds) WHO Classification of Tumours of the Digestive System 4th edn Vol. 3 (IARC Press, Lyon, 2010).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Raymond, E., Faivre, S., Hammel, P. & Ruszniewski, P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target. Oncol. 4, 253–254 (2009).
Solcia, E., Rindi, G. & Capella, C. in Histochemistry in Pathology 2nd edn (eds Felipe, M. I. & Lake, B. D.) 397–409 (Churchill-Livingstone, Edinburgh, 1990).
Wiedenmann, B. & Huttner, W. B. Synaptophysin and chromogranins/secretogranins—widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 58, 95–121 (1989).
Wiedenmann, B. et al. Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenterology 95, 1364–1374 (1988).
Adams, M. S. & Bronner-Fraser, M. Review: the role of neural crest cells in the endocrine system. Endocr. Pathol. 20, 92–100 (2009).
Schonhoff, S. E., Giel-Moloney, M. & Leiter, A. B. Minireview: Development and differentiation of gut endocrine cells. Endocrinology 145, 2639–2644 (2004).
Lepage, C., Rachet, B. & Coleman, M. P. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132, 899–904 (2007).
Soga, J. & Tazawa, K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 28, 990–998 (1971).
Arrigoni, M. G., Woolner, L. B. & Bernatz, P. E. Atypical carcinoid tumors of the lung. J. Thorac. Cardiovasc. Surg. 64, 413–421 (1972).
Modlin, I. M. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008).
Zerbi, A. et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am. J. Gastroenterol. 105, 1421–1429 (2010).
Oberndorfer, S. Karzinoide Tumoren des Du¨nndarms. Frankf Z. Pathol. Int. 1, 425–432 (1907).
Rindi, G., Capella, C. & Solcia, E. in Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors (eds Mignon, M. & Colombel, J. F.) 177–191 (John Libbey Eurotext, Montrouge, 1999).
Gould, V. E. Neuroendocrinomas and neuroendocrine carcinomas: APUD cell system neoplasms and their aberrant secretory activities. Pathol. Annu. 12, 33–62 (1977).
Gould, V. E. & Chejfec, G. Ultrastructural and biochemical analysis of “undifferentiated” pulmonary carcinomas. Hum. Pathol. 9, 377–384 (1978).
Travis, W. D. et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 15, 529–553 (1991).
Rindi, G. et al. in WHO Classification of Tumours of the Digestive System 4th edn Vol. 3 (eds Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D.) 10–12 (IARC Press, Lyon, 2010).
Solcia, E., Klöppel, G. & Sobin, L. H. World Health Organization International Histological Classification of Tumours: Histological Typing of Endocrine Tumours 2nd edn (Springer-Verlag, New York, 2000).
Rindi, G. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006).
Rindi, G. et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757–762 (2007).
Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. (eds) TNM Classification of Malignant Tumours 7th edn (Wiley-Blackwell, Chichester, 2009).
Edge, S. B. et al. (eds) AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Yang, Q., Bermingham, N. A., Finegold, M. J. & Zoghbi, H. Y. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294, 2155–2158 (2001).
Jenny, M. et al. Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium. EMBO J. 21, 6338–6347 (2002).
Desai, S. et al. Nkx2.2 regulates cell fate choice in the enteroendocrine cell lineages of the intestine. Dev. Biol. 313, 58–66 (2008).
Rindi, G. et al. Targeted ablation of secretin-producing cells in transgenic mice reveals a common differentiation pathway with multiple enteroendocrine cell lineages in the small intestine. Development 126, 4149–4156 (1999).
Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41–46 (2004).
Xu, X. et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132, 197–207 (2008).
Puri, S. & Hebrok, M. Cellular plasticity within the pancreas–lessons learned from development. Dev. Cell 18, 342–356 (2010).
Lichtenauer, U. D. & Beuschlein, F. The tumor stem cell concept-implications for endocrine tumors? Mol. Cell. Endocrinol. 300, 158–163 (2009).
Thomas, D., Friedman, S. & Lin, R. Y. Thyroid stem cells: lessons from normal development and thyroid cancer. Endocr. Relat. Cancer 15, 51–58 (2008).
Powers, J. F., Evinger, M. J., Zhi, J., Picard, K. L. & Tischler, A. S. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 147, 928–937 (2007).
Zhang, P., Zuo, H., Ozaki, T., Nakagomi, N. & Kakudo, K. Cancer stem cell hypothesis in thyroid cancer. Pathol. Int. 56, 485–489 (2006).
Heiskala, K., Arola, J., Heiskala, M. & Andersson, L. C. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol. Histopathol. 25, 63–72 (2010).
van Eeden, S. et al. Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology 51, 763–773 (2007).
Westerman, B. A. et al. Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors. Int. J. Biol. Markers 22, 114–123 (2007).
Schmitt, A. M. et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am. J. Surg. Pathol. 32, 420–425 (2008).
Lejonklou, M. H., Edfeldt, K., Johansson, T. A., Stålberg, P. & Skogseid, B. Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells. Pancreas 38, 259–266 (2009).
Garcia-Carbonero, R. et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794–1803 (2010).
Ito, T. et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010).
Niederle, M. B., Hackl, M., Kaserer, K. & Niederle, B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr. Relat. Cancer 17, 909–918 (2010).
Hruban, R. H., Bishop Pitman, M. & Klimstra, D. S. Tumors of the Pancreas 6th edn (American Registry of Pathology Press, Washington DC, 2007).
Klöppel, G. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90, 162–166 (2009).
Klimstra, D. S. et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am. J. Surg. Pathol. 34, 300–313 (2010).
Volante, M., Rindi, G. & Papotti, M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 449, 499–506 (2006).
Tönnies, H. et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48, 536–541 (2001).
Pizzi, S. et al. Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer 98, 1273–1282 (2003).
Furlan, D. et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin. Cancer Res. 10, 947–957 (2004).
Kim do, H. et al. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 47, 84–92 (2008).
Missiaglia, E. et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245–255 (2010).
Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).
Löllgen, R. M., Hessman, O., Szabo, E., Westin, G. & Akerström, G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int. J. Cancer 92, 812–815 (2001).
Wang, G. G. et al. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod. Pathol. 18, 1079–1087 (2005).
Cunningham, J. L. et al. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer 50, 82–94 (2011).
Rigaud, G. et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res. 61, 285–292 (2001).
Jonkers, Y. M. et al. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocrine Relat. Cancer 14, 769–779 (2007).
Calender, A. in Handbook of Neuroendocrine Tumours (eds Caplin, M. & Kvols, L.) 55–81 (Bioscientifica, Bristol, 2006).
de Herder, W. W. et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84, 183–188 (2006).
Jensen, R. T. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84, 173–182 (2006).
Eriksson, B. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors–well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8–19 (2008).
Jensen, R. T. in Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumours (eds Mignon, M. & Colombel, J. F.) 192–219 (John Libbey Eurotext, Paris, 1999).
Modlin, I. M. et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med. J. Aust. 193, 46–52 (2010).
Yao, J. C. et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 28, 69–76 (2010).
Massironi, S. et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am. J. Gastroenterol. 105, 2072–2078 (2010).
Rufini, V., Calcagni, M. L. & Baum, R. P. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36, 228–247 (2006).
Scarsbrook, A. F. et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 27, 455–477 (2007).
Elsayes, K. M. et al. Imaging of carcinoid tumors: spectrum of findings with pathologic and clinical correlation. J. Comput. Assist. Tomogr. 35, 72–80 (2011).
Kwekkeboom, D. J. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 90, 184–189 (2009).
Sundin, A., Vullierme, M. P., Kaltsas, G. & Plöckinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 90, 167–183 (2009).
Kiesslich, R. et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 133, 1769–1778 (2007).
May, A. et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 53, 634–640 (2004).
Swain, P. & Fritscher-Ravens, A. Role of video endoscopy in managing small bowel disease. Gut 53, 1866–1875 (2004).
Moglia, A., Menciassi, A., Dario, P. & Cuschieri, A. Capsule endoscopy: progress update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 6, 353–362 (2009).
Carrasquillo, J. A. & Chen, C. C. Molecular imaging of neuroendocrine tumors. Semin. Oncol. 37, 662–679 (2010).
Kwekkeboom, D. J. et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, R53–R73 (2010).
Ambrosini, V., Tomassetti, P., Franchi, R. & Fanti, S. Imaging of NETs with PET radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging 54, 16–23 (2010).
Putzer, D. et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q. J. Nucl. Med. Mol. Imaging 54, 68–75 (2010).
Yao, J. C. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 21, 163–172 (2007).
Strosberg, J. R. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117, 268–275 (2011).
Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656–4663 (2009).
Pape, U. F. et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113, 256–265 (2008).
Jann, H. et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer 117, 3332–3341 (2011).
de Herder, W. W., O'Toole, D., Rindi, G. & Wiedenmann, B. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors Part 1—Stomach, Duodenum and Pancreas. Neuroendocrinology 84, 151–216 (2006).
de Herder, W. W., O'Toole, D., Rindi, G. & Wiedenmann, B. ENETS Consensus Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumors Part 2—Midgut and Hindgut Tumors. Neuroendocrinology 87, 1–63 (2008).
Oberg, K. E., Reubi, J. C., Kwekkeboom, D. J. & Krenning, E. P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139, 742–753 (2010).
Roberts, W. C. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am. J. Cardiol. 80, 251–256 (1997).
Dumoulein, M. et al. Carcinoid heart disease: case and literature review. Acta Cardiol. 65, 261–264 (2010).
Schmidt, C., Bloomston, M. & Shah, M. H. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene 30, 1497–1505 (2011).
Ahmadzadehfar, H., Biersack, H. J. & Ezziddin, S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin. Nucl. Med. 40, 105–121 (2010).
Crocetti, L. & Lencioni, R. Radiofrequency ablation of pulmonary tumors. Eur. J. Radiol. 75, 23–27 (2010).
Wiedenmann, B., Pavel, M. & Kos-Kudla, B. From targets to treatments—a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology (in press).
Bertino, E. M., Confer, P. D., Colonna, J. E., Ross, P. & Otterson, G. A. Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 115, 4434–4441 (2009).
Bajetta, E. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59, 637–642 (2007).
Ceppi, P. et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin. Cancer Res. 14, 1059–1064 (2008).
O'Toole, D. et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, 847–856 (2010).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
Kulke, M. H. et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15, 338–345 (2009).
Hlatky, R., Suki, D. & Sawaya, R. Carcinoid metastasis to the brain. Cancer 101, 2605–2613 (2004).
Pool, S. E. et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med. 40, 209–218 (2010).
Bushnell, D. L. Jr et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652–1659 (2010).
Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).
Nilsson, O., Arvidsson, Y., Johanson, V., Forssell-Aronsson, E. & Ahlman, H. New medical strategies for midgut carcinoids. Anticancer Agents Med. Chem. 10, 250–269 (2010).
Author information
Authors and Affiliations
Contributions
Both authors researched data for the article, provided substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
G. Rindi declares associations with the following companies: Ipsen (consultant), Novartis (speakers bureau), Pfizer (speakers bureau). B. Wiedenmann declares associations with the following companies: Ipsen (consultant, speakers bureau), Lexicon (consultant), Novartis (consultant, speakers bureau), Pfizer (consultant, speakers bureau).
Rights and permissions
About this article
Cite this article
Rindi, G., Wiedenmann, B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8, 54–64 (2012). https://doi.org/10.1038/nrendo.2011.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.120
This article is cited by
-
Radiomics analysis from magnetic resonance imaging in predicting the grade of nonfunctioning pancreatic neuroendocrine tumors: a multicenter study
European Radiology (2023)
-
Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors
Endocrine Pathology (2023)
-
The Spectrum of Endocrine Pathology
Endocrine Pathology (2023)
-
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Endocrine Pathology (2022)
-
Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon
Medical Oncology (2022)